Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo
Key clinical point: Blinatumomab was superior to high-risk consolidation 3 chemotherapy in a phase 3 clinical trial among children with high-risk first-relapse acute lymphoblastic leukemia.
Major finding: Events occurred among 18/54 (33.3%) in the blinatumomab arm and 31/54 (57.4%) in the high-risk consolidation 3 arm, with a median event-free survival of “not reached” and 7.4 months, respectively.
Study details: The open-label, controlled phase 3 trial randomized 104 children with ALL.
Disclosures: Dr. Locatelli disclosed relationships with multiple companies.
Citation:
Locatelli F et al. ASH 2020, Abstract 268.